ASX - By Stock
|
NOX |
Re:
Ann: March 2023 Quarterly Activities Report and Appendix 4C
|
|
RBx
|
26 |
9.1K |
5 |
26/04/23 |
26/04/23 |
ASX - By Stock
|
26
|
9.1K
|
5
|
|
ASX - By Stock
|
NOX |
Re:
Ann: Noxopharm to Prioritise Cutting-Edge Chroma & Sofra Programs
|
|
RBx
|
67 |
28K |
0 |
20/04/23 |
20/04/23 |
ASX - By Stock
|
67
|
28K
|
0
|
|
ASX - By Stock
|
NOX |
Re:
Ann: Noxopharm to Prioritise Cutting-Edge Chroma & Sofra Programs
|
|
RBx
|
67 |
28K |
9 |
15/04/23 |
15/04/23 |
ASX - By Stock
|
67
|
28K
|
9
|
|
ASX - By Stock
|
NOX |
Re:
IONIC may yet be a winner
|
|
RBx
|
57 |
22K |
8 |
24/03/23 |
24/03/23 |
ASX - By Stock
|
57
|
22K
|
8
|
|
ASX - By Stock
|
NOX |
Re:
IONIC may yet be a winner
|
|
RBx
|
57 |
22K |
7 |
23/03/23 |
23/03/23 |
ASX - By Stock
|
57
|
22K
|
7
|
|
ASX - By Stock
|
NOX |
IONIC may yet be a winner
|
|
RBx
|
57 |
22K |
14 |
07/03/23 |
07/03/23 |
ASX - By Stock
|
57
|
22K
|
14
|
|
ASX - By Stock
|
NOX |
Professor Kelly comments...
|
|
RBx
|
13 |
6.3K |
17 |
06/01/23 |
06/01/23 |
ASX - By Stock
|
13
|
6.3K
|
17
|
|
ASX - By Stock
|
KZA |
Re:
Ann: Withdrawal of resolution
|
|
RBx
|
18 |
7.0K |
9 |
14/11/22 |
14/11/22 |
ASX - By Stock
|
18
|
7.0K
|
9
|
|
ASX - By Stock
|
NOX |
Re:
AGM
|
|
RBx
|
46 |
11K |
5 |
09/11/22 |
09/11/22 |
ASX - By Stock
|
46
|
11K
|
5
|
|
ASX - By Stock
|
NOX |
Re:
AGM
|
|
RBx
|
46 |
11K |
4 |
08/11/22 |
08/11/22 |
ASX - By Stock
|
46
|
11K
|
4
|
|
ASX - By Stock
|
NOX |
Re:
AGM
|
|
RBx
|
46 |
11K |
0 |
08/11/22 |
08/11/22 |
ASX - By Stock
|
46
|
11K
|
0
|
|
ASX - By Stock
|
NOX |
AGM
|
|
RBx
|
46 |
11K |
9 |
08/11/22 |
08/11/22 |
ASX - By Stock
|
46
|
11K
|
9
|
|
ASX - By Stock
|
NOX |
AACR
|
|
RBx
|
5 |
1.4K |
14 |
13/09/22 |
13/09/22 |
ASX - By Stock
|
5
|
1.4K
|
14
|
|
ASX - By Stock
|
KZA |
Re:
Ann: GBM Agile Update
|
|
RBx
|
178 |
66K |
8 |
02/08/22 |
02/08/22 |
ASX - By Stock
|
178
|
66K
|
8
|
|
ASX - By Stock
|
NOX |
ASCO thoughts
|
|
RBx
|
11 |
4.4K |
25 |
28/05/22 |
28/05/22 |
ASX - By Stock
|
11
|
4.4K
|
25
|
|
ASX - By Stock
|
NOX |
LuPIN thoughts
|
|
RBx
|
24 |
8.7K |
16 |
14/05/22 |
14/05/22 |
ASX - By Stock
|
24
|
8.7K
|
16
|
|
ASX - By Stock
|
KZA |
Re:
Mutational Landscape of PI3K-AKT-mTOR Pathway in Breast Cancer: Implications for Targeted Therapeutics
|
|
RBx
|
13 |
6.3K |
1 |
17/04/22 |
17/04/22 |
ASX - By Stock
|
13
|
6.3K
|
1
|
|
ASX - By Stock
|
NOX |
Patent news
|
|
RBx
|
0 |
717 |
16 |
04/02/22 |
04/02/22 |
ASX - By Stock
|
0
|
717
|
16
|
|
ASX - By Stock
|
NOX |
GK's letter to shareholders
|
|
RBx
|
0 |
584 |
15 |
01/02/22 |
01/02/22 |
ASX - By Stock
|
0
|
584
|
15
|
|
ASX - By Stock
|
NOX |
Re:
IONIC Update
|
|
RBx
|
2 |
1.8K |
18 |
01/02/22 |
01/02/22 |
ASX - By Stock
|
2
|
1.8K
|
18
|
|
ASX - By Stock
|
NOX |
Another Patent Granted
|
|
RBx
|
3 |
1.8K |
16 |
06/01/22 |
06/01/22 |
ASX - By Stock
|
3
|
1.8K
|
16
|
|
ASX - By Stock
|
NOX |
Re:
The boy who cried wolf
|
|
RBx
|
13 |
4.9K |
9 |
06/01/22 |
06/01/22 |
ASX - By Stock
|
13
|
4.9K
|
9
|
|
ASX - By Stock
|
NOX |
Re:
The boy who cried wolf
|
|
RBx
|
13 |
4.9K |
3 |
06/01/22 |
06/01/22 |
ASX - By Stock
|
13
|
4.9K
|
3
|
|
ASX - By Stock
|
NOX |
IONIC Update
|
|
RBx
|
2 |
1.8K |
19 |
05/01/22 |
05/01/22 |
ASX - By Stock
|
2
|
1.8K
|
19
|
|
ASX - By Stock
|
NOX |
Re:
Ann: Noxopharm Announces Leadership Transition
|
|
RBx
|
26 |
10K |
20 |
05/01/22 |
05/01/22 |
ASX - By Stock
|
26
|
10K
|
20
|
|
ASX - By Stock
|
NOX |
Re:
How can we do better?
|
|
RBx
|
23 |
8.8K |
13 |
23/12/21 |
23/12/21 |
ASX - By Stock
|
23
|
8.8K
|
13
|
|
ASX - By Stock
|
NOX |
How can we do better?
|
|
RBx
|
23 |
8.8K |
6 |
22/12/21 |
22/12/21 |
ASX - By Stock
|
23
|
8.8K
|
6
|
|
ASX - By Stock
|
NOX |
Re:
Pharmorage
|
|
RBx
|
15 |
6.7K |
17 |
16/12/21 |
16/12/21 |
ASX - By Stock
|
15
|
6.7K
|
17
|
|
ASX - By Stock
|
NOX |
Re:
HIMR
|
|
RBx
|
6 |
2.2K |
13 |
10/12/21 |
10/12/21 |
ASX - By Stock
|
6
|
2.2K
|
13
|
|
ASX - By Stock
|
NOX |
Patent Grant
|
|
RBx
|
2 |
880 |
17 |
10/12/21 |
10/12/21 |
ASX - By Stock
|
2
|
880
|
17
|
|
ASX - By Stock
|
NOX |
HIMR
|
|
RBx
|
6 |
2.2K |
15 |
10/12/21 |
10/12/21 |
ASX - By Stock
|
6
|
2.2K
|
15
|
|
ASX - By Stock
|
KZA |
Re:
KZA Chart
|
|
RBx
|
559 |
160K |
3 |
08/12/21 |
08/12/21 |
ASX - By Stock
|
559
|
160K
|
3
|
|
ASX - By Stock
|
NOX |
Re:
Latest Newsletter
|
|
RBx
|
12 |
3.6K |
13 |
08/12/21 |
08/12/21 |
ASX - By Stock
|
12
|
3.6K
|
13
|
|
ASX - By Stock
|
NOX |
Re:
Pharmorage
|
|
RBx
|
15 |
6.7K |
10 |
01/12/21 |
01/12/21 |
ASX - By Stock
|
15
|
6.7K
|
10
|
|
ASX - By Stock
|
NOX |
Pharmorage
|
|
RBx
|
15 |
6.7K |
14 |
29/11/21 |
29/11/21 |
ASX - By Stock
|
15
|
6.7K
|
14
|
|
ASX - By Stock
|
NOX |
Re:
Ann: Noxopharm 2021 AGM Corporate Presentation
|
|
RBx
|
10 |
4.3K |
11 |
19/11/21 |
19/11/21 |
ASX - By Stock
|
10
|
4.3K
|
11
|
|
ASX - By Stock
|
NOX |
Re:
Ann: Noxopharm 2021 AGM Corporate Presentation
|
|
RBx
|
10 |
4.3K |
10 |
19/11/21 |
19/11/21 |
ASX - By Stock
|
10
|
4.3K
|
10
|
|
ASX - By Stock
|
NOX |
Re:
AGM comments
|
|
RBx
|
11 |
3.0K |
0 |
17/11/21 |
17/11/21 |
ASX - By Stock
|
11
|
3.0K
|
0
|
|
ASX - By Stock
|
NOX |
Re:
AGM comments
|
|
RBx
|
11 |
3.0K |
0 |
17/11/21 |
17/11/21 |
ASX - By Stock
|
11
|
3.0K
|
0
|
|
ASX - By Stock
|
NOX |
Re:
AGM comments
|
|
RBx
|
11 |
3.0K |
11 |
17/11/21 |
17/11/21 |
ASX - By Stock
|
11
|
3.0K
|
11
|
|
ASX - By Stock
|
NOX |
AGM comments
|
|
RBx
|
11 |
3.0K |
23 |
17/11/21 |
17/11/21 |
ASX - By Stock
|
11
|
3.0K
|
23
|
|
ASX - By Stock
|
NOX |
Re:
Ann: Licencing Deal Expands Noxopharm Drug Opportunities
|
|
RBx
|
12 |
3.4K |
6 |
17/11/21 |
17/11/21 |
ASX - By Stock
|
12
|
3.4K
|
6
|
|
ASX - By Stock
|
NOX |
Re:
Ann: Licencing Deal Expands Noxopharm Drug Opportunities
|
|
RBx
|
12 |
3.4K |
8 |
17/11/21 |
17/11/21 |
ASX - By Stock
|
12
|
3.4K
|
8
|
|
ASX - By Stock
|
NOX |
Re:
Prediction
|
|
RBx
|
9 |
2.4K |
10 |
16/11/21 |
16/11/21 |
ASX - By Stock
|
9
|
2.4K
|
10
|
|
ASX - By Stock
|
NOX |
Prediction
|
|
RBx
|
9 |
2.4K |
12 |
16/11/21 |
16/11/21 |
ASX - By Stock
|
9
|
2.4K
|
12
|
|
ASX - By Stock
|
NOX |
Re:
Ann: Veyonda and Opdivo IONIC Study First Patient Dosed
|
|
RBx
|
37 |
13K |
15 |
11/11/21 |
11/11/21 |
ASX - By Stock
|
37
|
13K
|
15
|
|
ASX - By Stock
|
NOX |
Observations
|
|
RBx
|
8 |
2.7K |
16 |
03/11/21 |
03/11/21 |
ASX - By Stock
|
8
|
2.7K
|
16
|
|
ASX - By Stock
|
NOX |
Re:
Sarcoma trial to start Nov 15
|
|
RBx
|
15 |
5.1K |
3 |
02/11/21 |
02/11/21 |
ASX - By Stock
|
15
|
5.1K
|
3
|
|
ASX - By Stock
|
NOX |
Sarcoma trial to start Nov 15
|
|
RBx
|
15 |
5.1K |
19 |
31/10/21 |
31/10/21 |
ASX - By Stock
|
15
|
5.1K
|
19
|
|
ASX - By Stock
|
NOX |
Re:
Ann: September 2021 Quarterly Activities Report and Appendix 4C
|
|
RBx
|
16 |
4.1K |
15 |
15/10/21 |
15/10/21 |
ASX - By Stock
|
16
|
4.1K
|
15
|
|